Melanoma Insights for Professionals Melanoma Institute Australia

Our latest podcast explores the innovative approach of neoadjuvant  immunotherapy - administering checkpoint inhibitor immunotherapy before the surgical removal of  melanoma. This promising approach is creating a buzz among multidisciplinary clinicians and researchers globally as the potential  benefits for melanoma patients are being realised.

Although neoadjuvant therapy is well established in oncology, using immunotherapy in melanoma has revolutionised patient outcomes through significant improvements in overall survival rates.

In this engaging podcast, MIA’s Prof Georgina Long AO leads a discussion with multidisciplinary world leaders in the neoadjuvant space to discuss:


the benefits of checkpoint inhibitor immunotherapy
the role of the pathologist in the assessment of neoadjuvant tissue
the impact of surgical decision-making as neoadjuvant becomes mainstay treatment
options for treatment-refractory patients
the role of checkpoint inhibitor immunotherapy in non-melanoma skin cancer.

The discussion concludes with case studies to summarise key learnings.

This podcast is suitable for Medical Oncologists, Oncologists,  Surgeons, Pathologists, Dermatologists, GPs, Oncology Nurses and other  healthcare professionals.

SPEAKERS:


Prof Georgina Long AO - Co-Medical Director,  Melanoma Institute Australia | Chair, Melanoma Medical Oncology and  Translational Research, Melanoma Institute Australia and Royal North  Shore Hospital, The University of Sydney
Prof Richard Scolyer AO - Co-Medical Director,  Melanoma Institute Australia | Pathologist, Melanoma Institute  Australia, Senior Staff Specialist, Royal Prince Alfred Hospital |  Clinical Professor, The University of Sydney
A/Prof Alexander Menzies - Medical Oncologist,  Melanoma Institute Australia, Royal North Shore and Mater Hospitals |  Associate Professor of Melanoma Medical Oncology, The University of  Sydney
A/Prof Alexander van Akkooi - Associate Professor  in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal  Prince Alfred Hospital, The University of Sydney

KEY CLINICAL TRIALS


SWOG
PRADO
OpACIN-neo
NADINA

FURTHER EDUCATION


The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists 

Please note that this podcast was accurate at the time of recording  (February 2023) but may not reflect the rapidly evolving treatment  landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Lentigo maligna – a subtype of in situ melanoma – presents diagnostic and treatment challenges for clinicians.

In this podcast, Dr Michael Rtshiladze leads a multidisciplinary  discussion to unravel our understanding of the pathology, diagnosis and  management of lentigo maligna, including:


clinical and histological presentation
tools to diagnose and monitor lesions
the impact of different types of biopsies
the importance of mapping the extent of lesions
the challenge of surgical management in cosmetically sensitive areas
the role of radiation therapy and topical treatments
when to refer your patient.

The discussion concludes with a case study to summarise key learnings.

This podcast is suitable for Plastic Surgeons, General Surgeons,  Dermatologists, Oncologists, Pathologists, GPs, Nurses and other  healthcare professionals.

SPEAKERS


Dr Michael Rtshiladze - Plastic and Reconstructive  Surgeon, Melanoma Institute Australia, Royal Prince Alfred Hospital, The  Prince of Wales Hospital, St George Hospital and Sydney Children’s  Hospital
Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital
Prof Pascale Guitera - Dermatologist, Melanoma  Institute Australia | Director, Sydney Melanoma Diagnostic Centre at  Royal Prince Alfred Hospital | Professorial Research Fellow, The  University of Sydney
Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia | Clinical Professor, The University of Sydney

RESOURCE AND REFERENCE


Lentigo Maligna Patient Information Brochure
Crouch G, Sinha S, Lo S, Saw RPM, Lee KK, Stretch J, Shannon K, Guitera P, Scolyer RA, Thompson JF & Ch'ng S. Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. Eur J Surg Oncol. 2021 May;47(5):1145-1151.

Please note that this podcast was accurate at the time of recording  (December 2022) but may not reflect the rapidly evolving treatment  landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Despite recent advances in management of primary uveal melanoma, more than half of patients develop metastatic disease – often with poor outcomes. New therapeutic approaches to metastatic disease are vital.

In this podcast, A/Prof Matteo Carlino interviews fellow Medical  Oncologist Prof Georgina Long AO and Ophthalmologist A/Prof Max Conway on our latest understanding of the diagnosis and management of early and advanced uveal melanoma, including:


presentation and diagnostic process
current treatment options and rationale for local therapy in early melanoma
determining which patients are suitable for screening for metastatic disease
developing a surveillance plan based on risk of recurrence
the different activity of systemic therapy in uveal versus cutaneous melanoma
importance of the multidisciplinary team
activity of tebentafusp in advanced uveal melanoma
the current clinical trial landscape.

This podcast is suitable for Oncologists, Ophthalmologists, GPs, Oncology Nurses and other healthcare professionals.

SPEAKERS


A/Prof Matteo Carlino - Medical Oncologist, Melanoma  Institute Australia, Westmead and Blacktown Hospitals Clinical  Associate Professor, The University of Sydney
Prof Georgina Long AO - Co-Medical Director,  Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney
A/Prof Max Conway - Ophthalmologist, Save Sight Institute, Sydney Eye Hospital and The University of Sydney

RESOURCES


Early Ocular Melanoma Patient Information Brochure
Advanced Ocular Melanoma Patient Information Brochure
Melanoma Education Portal

Please note that this podcast was accurate at the time of recording  (November 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, BMS, Novartis and HEINE.

Treating clinicians rely on pathology to help diagnose and stage their patient which fundamentally determines the treatment management  plan. Therefore, it is incredibly important to get it right in the first place.

In this engaging podcast aimed at GPs, our multidisciplinary experts discuss:


Why can it be challenging to get the pathology right?
What clinical information is important to include on the pathology request form?
How is the pathology report structured?
How is the specimen processed?
What biopsy is key to maximising the diagnostic and prognostic interpretation of the pathology?
Are partial biopsies ever appropriate?
What implications does the type of biopsy have for subsequent surgery?
When does a GP need to refer their patient?

The discussion is concluded with two case studies to summarise key learnings.

This podcast is suitable for GPs, Dermatologists, Surgeons, Oncologists, Pathologists and other healthcare professionals.

SPEAKERS


Dr Adrian Quek - Skin Cancer GP, Melanoma Institute Australia and The Chatswood Skin Cancer Clinic
Dr Alison Potter - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital
Dr Nigel Maher - McMurtrie Cancer Pathology Fellow, Melanoma Institute Australia
A/Prof Alexander van Akkooi - Associate Professor  in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney
Dr Niamh-Anna O’Sullivan - Specialist Dermatologist, Melanoma Institute Australia

HOST


Danielle Fischer - Education Program Manager, Melanoma Institute Australia

Please note that this podcast was accurate at the time of recording (June 2022) but may not reflect the rapidly evolving treatment landscape  and approvals in Australia.

For more practice-changing education, visit our Melanoma Education Portal.

MIA's Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.

The role of pathology in the diagnosis and treatment of melanoma is pivotal to optimal patient care. With so many disciplines relying on the pathologist for accurate diagnoses and critical pathological information, we decided to reach out to our clinical melanoma community to ask them for their critical pathology questions. 

In this podcast, Prof John Thompson AO and Prof Fergal Moloney pick at the brain of the world's leading melanoma Pathologist, Prof Richard Scolyer AO, as they discuss: 


The clinical information needed to aid diagnosis 
The role of artificial intelligence and computing in pathology 
Overdiagnosis of melanoma 
The problem of partial biopsies 
Diagnosing borderline lesions 
What is a melanocytoma and how should it be managed 
What is an irritated naevus 
Dysplastic naevi and appropriate management 

This podcast is suitable for GPs, Dermatologists, Surgeons, Oncologists, Pathologists and other healthcare professionals. 

SPEAKERS 

Prof Richard Scolyer AO - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney 

Prof John Thompson AO - Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney | Member, Melanoma Institute Australia 

Prof Fergal Moloney - Consultant Dermatologist, Melanoma Institute Australia and Mater Misericordiae University Hospital | Clinical Professor, University College, Dublin 

Please note that this podcast was accurate at the time of recording (June 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. 

For more practice-changing education, visit our Melanoma Education Portal. 

MIA's Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.

Cancer drugs have rapidly evolved in the last decade. Alongside the significant benefits are new toxicity profiles that clinicians need to be aware of and manage. In this podcast, A/Prof Carlino interviews fellow Medical Oncologist Prof Georgina Long AO on the adverse events/toxicities associated with targeted therapies (combination BRAF/MEK inhibitors) and immunotherapies (anti-PD-1, anti-LAG-3 and anti-CTLA-4), particularly in melanoma, and how they should be managed.

This podcast is suitable for Oncologists, Emergency Medicine Physicians, GPs, Oncology Nurses and other healthcare professionals.

SPEAKERS


Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney
A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals Clinical Associate Professor, The University of Sydney

Please note that this podcast was accurate at the time of recording (May 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.